Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2019 09:15 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia

More than 60% of patients have completed their 6-month treatment plan Topline results remain on track for year-end LAVAL, Quebec, June 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or...
May 23, 2019 17:00 ET | Source: Acasti Pharma, Inc.

Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

LAVAL, Québec, May 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of...
May 21, 2019 07:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

LAVAL, Québec, May 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
May 15, 2019 07:55 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

LAVAL, Québec, May 15, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development...
May 10, 2019 07:30 ET | Source: Acasti Pharma, Inc.

Acasti Settles Claims with Former Chief Executive Officer

LAVAL, Québec, May 10, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has settled regarding claims made against the...
April 24, 2019 08:00 ET | Source: Acasti Pharma, Inc.

Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

LAVAL, Quebec, April 24, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and...
April 15, 2019 09:15 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

More Than 40% of Patients Have Completed Their 6 Month Treatment Plan Top Line Results Remain On Track For Year-End Annual Performance Grants of Stock Options and Amendment of Stock Option Plan...
April 01, 2019 09:20 ET | Source: Acasti Pharma, Inc.

Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal LAVAL, Québec, April 01, 2019 (GLOBE...
March 26, 2019 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

LAVAL, Quebec, March 26, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and...
March 13, 2019 08:30 ET | Source: Acasti Pharma, Inc.

Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

LAVAL, Quebec, March 13, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and...